4 completed, 1 active not recruiting. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Active not recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow LY3295668 erbumine: new trials by email Literature Review of LY3295668 erbumine trials Research Report on LY3295668 erbumine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer Aurora A Kinase Inhibitor LY3295668, Osimertinib - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2022-02-17 | 2026-09-18 |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma LY3295668 Erbumine, Topotecan, Cyclophosphamide - Neuroblastoma | Phase 1 | Active not recruiting | Eli Lilly and Company | 71 | 2020-06-11 | 2026-08-21 |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body LY3295668 Erbumine, Endocrine therapy, Midazolam - Metastatic Breast Cancer | Phase 1 | Completed | Eli Lilly and Company | 5 | 2019-08-02 | 2020-06-01 |
| A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer LY3295668 Erbumine - Small Cell Lung Cancer | Phase 1 | Completed | Eli Lilly and Company | 48 | 2019-07-16 | 2021-08-05 |
| A Study of AK-01 (LY3295668) in Solid Tumors LY3295668 - Neoplasms, Neoplasm Metastasis | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 13 | 2017-05-29 | 2021-07-02 |
Epilepsy (3) · Breast Neoplasms (2) · Small Cell Lung Carcinoma (2) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1) · Triple Negative Breast Neoplasms (1)
Eli Lilly and Company (4) · M.D. Anderson Cancer Center (1)
United States (4) · Belgium (3) · France (2) · Japan (2) · Spain (2) · United Kingdom (2) · Australia (1) · Canada (1) · Germany (1) · Italy (1) · South Korea (1) · Turkey (Türkiye) (1)
Xiuning Le (1)
2018 (2), 2019 (1)